ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy-Reference-Cited by-同舟云学术

ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy

Published:2014-12-11 Issue:12 Volume:9 Page:e114646
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Li Jian-wei,Mo Miao,Yu Ke-da,Chen Can-ming,Hu Zhen,Hou Yi-feng,Di Gen-hong,Wu Jiong,Shen Zhen-zhou,Shao Zhi-ming,Liu Guang-yu

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference33 articles.

1. Breast cancer. Clinical practice guidelines in oncology;RW Carlson;J Natl Compr Canc Netw,2009

2. Long-term morbidity following axillary dissection in breast cancer patients–clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors;T Kuehn;Breast Cancer Res Treat,2000

3. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection;T Ashikaga;J Surg Oncol,2010

4. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis;D Mauri;J Natl Cancer Inst,2005

5. Neoadjuvant chemotherapy for operable breast cancer;JS Mieog;Br J Surg,2007

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oncoplastic breast surgery in Europe;Gland Surgery;2024-02

2. DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer;Cancers;2023-03-06

3. Axillary Downstaging and the Impact of Clinical Axillary Status on Efficacy of Neoadjuvant Therapy for HER2-Positive Breast Cancer: A Network Meta-Analysis;Technology in Cancer Research & Treatment;2023-01

4. Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease;JAMA Surgery;2021-04-21

5. Predictive value of tumor-infiltrating lymphocytes for pathological response to neoadjuvant chemotherapy in breast cancer patients with axillary lymph node metastasis;Surgery Today;2020-10-14